AZ and Innate to collaborate in immuno-oncology

ASTRAZENECA AND Innate Pharma ANNOUNCE

GLOBAL CO-DEVELOPMENT AND COMMERCIALISATION COLLABORATION FOR iph2201 IN IMMUNO
-ONCOLOGY

AstraZeneca and MedImmune, the Company's global biologics research and
development arm, today announced that they have entered into a collaboration to
accelerate and broaden the development of Innate Pharma SA's proprietary anti
-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1
immune checkpoint inhibitor developed by MedImmune. Currently in Phase II
development, IPH2201 is a potential first-in-class humanised IgG4 antibody.
NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of
Natural Killer (NK) and cytotoxic T-cells.

The initial development plan includes: Phase II combination clinical trials with
MEDI4736 in solid tumours; multiple Phase II trials planned by Innate to study
IPH2201 both as monotherapy and in combination with currently approved
treatments across a range of cancers; and the development of associated
biomarkers.

The combination of IPH2201 with MEDI4736 adds to the broad programme of immuno
-oncology combination trials that AstraZeneca and MedImmune have planned and
underway. The studies aim to address multiple immune pathways, harnessing
AstraZeneca's own extensive pipeline and working in partnership to explore the
significant potential of immunotherapies in transforming the way cancer patients
are treated.

Under the terms of the agreements, AstraZeneca will make an initial payment to
Innate of $250 million, which includes the consideration for exclusive global
rights to co-develop and commercialise IPH2201 in combination with MEDI4736, as
well as access to IPH2201 in monotherapy and other combinations in certain
treatment areas. AstraZeneca will pay a further $100 million prior to initiation
of Phase III development, as well as additional regulatory and sales-related
milestones. AstraZeneca will book all sales and will pay Innate double-digit
royalties on net sales. The arrangement includes the right for Innate to co
-promote in Europe for a 50% profit share in the territory.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: "We are pleased to
collaborate with Innate Pharma to bring this prospective first-in-class
treatment to cancer patients, further strengthening our broad immuno-oncology
pipeline. We believe that combination therapy in immuno-oncology has the
potential to be one of the most effective ways of treating cancer and that by
targeting both innate and acquired immunity we have the opportunity to deliver
important clinical benefit to patients across a range of cancers."

Hervé Brailly, CEO and co-founder of Innate Pharma, said: "This agreement allows
Innate Pharma to broaden and accelerate the development of anti-NKG2A while
preserving our innovative development plan. It provides Innate Pharma with the
capabilities and resources to transform the company towards late stage
development and potential commercial stage with co-promotion rights. We look
forward to partnering with AstraZeneca and MedImmune, leaders in immuno
-oncology, in this transforming transaction for Innate Pharma."

The transaction is subject to customary terms and conditions, including the
expiration or termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act, and is expected to become effective in the second
quarter of 2015. AstraZeneca's 2015 financial guidance is unaffected by today's
announcement.

About Innate Pharma's anti-NKG2A

IPH2201 is a first-in-class immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor infiltrating cytotoxic NK and CD8 T lymphocytes.

NKG2A is an inhibitory receptor binding HLA-E. By expressing HLA-E, cancer cells
can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently
up-regulated on cancer cells of many solid tumors or hematological malignancies.
IPH2201, a humanized IgG4, blocks the binding of NKG2A to HLA-E allowing
activation of NK and cytotoxic T cell responses.  Hence, IPH2201 may re
-establish a broad anti-tumor response mediated by NK and T cells. IPH2201 may
also enhance the cytotoxic potential of other therapeutic antibodies.

About MEDI4736

MEDI4736 is an investigational human monoclonal antibody directed against
programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid
detection by the immune system. MEDI4736 blocks these signals, countering the
tumour's immune-evading tactics.

MEDI4736 was accelerated into Phase III clinical development in non-small cell
lung cancer and head and neck cancer. The OCEANS clinical development programme
will evaluate MEDI4736 as monotherapy and in combination with a CTLA-4
(tremelimumab) in lung cancer, across the spectrum of the disease. In head and
neck cancer, MEDI4736 is being investigated both as monotherapy and in
combination with tremelimumab, looking at patients with different PD-L1
expression status who have failed on chemotherapy.

About Innate Pharma

Innate Pharma S.A. is a biopharmaceutical company discovering and developing
first-in-class therapeutic antibodies for the treatment of cancer and
inflammatory diseases. Its innovative approach has translated into major
alliances with leaders in the biopharmaceutical industry such as Bristol-Myers
Squibb and Novo Nordisk A/S. The Company has two clinical-stage programs in
immuno-oncology, a new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to recognize and kill
cancer cells. Innate Pharma's science also has potential in chronic inflammatory
diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had
99 employees as at December 31, 2014. Learn more about Innate Pharma at
www.innate-pharma.com.

About AstraZeneca in Oncology

Oncology is a therapeutic area in which AstraZeneca has deep-rooted heritage. It
will be potentially transformational for the company's future, becoming the
sixth growth platform. Our vision is to help patients by redefining the cancer
treatment paradigm and one-day eliminate cancer as cause of death. By 2020, we
are aiming to bring six new cancer medicines to patients.

Our broad pipeline of next-generation medicines is focused on four main disease
areas - ovarian, lung, breast, and haematological cancers. These are being
targeted through four key platforms - immuno-oncology, the genetic drivers of
cancer and resistance, DNA damage repair and antibody drug conjugates.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

AstraZeneca Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Jacob Lund                                  +46 8 553 260 20 (Sweden)

Michele Meixell                            + 1 302 885 2677 (US)

AstraZeneca Investor Enquiries

Thomas Kudsk Larsen               +44 20 7604 8199     mob: +44 7818 524185

Karl Hård                                     +44 20 7604 8123  mob: +44 7789
654364

Eugenia Litz                                +44 20 7604 8233    mob: +44 7884
735627

Craig Marks                                +44 20 7604 8591   mob: +44 7881
615764

Christer Gruvris                          +44 20 7604 8126 mob: +44 7827 836825

Innate Pharma Media Enquiries

Judith Aziza, Mob.:+33 (0)6 70 07 77 51

Marielle Bricman, Mob.:+33 (0)6 26 94 18 53

presse@atcg-partners.com (mb@atcg-partners.com)

Innate Pharma Investor Enquiries

Laure-Hélène Mercier

Director, Investor Relations

Tel.: +33 (0)4 30 30 30 87

investors@innate-pharma.com

24 April 2015

-ENDS-